NCT01881958撤回1 期
The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- efficacy will be measured by comparing Hemoglobin A1c
研究概览
简要总结
Type 1 diabetes is caused by an autoimmune process resulting in a selective destruction of the pancreatic insulin-secreting beta-cell. DiaPep277® is a small, lyophilized powder containing 24 Amino-acids. We have proved in former studies that DiaPep277® can slow down beta cells destruction in the pancreas and therefore decelerate the progress of Diabetes.
The objective of the study is to assess the efficacy and safety of administrating DiaPep277® in type 1 diabetes patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fasting C-peptide levels >= 0.2nmol/L.
- •Diagnosis of type 1 diabetes
- •No pregnancies or planned pregnancies of female subjects
排除标准
- •The subject has any significant diseases or conditions, including psychiatric disorders and substance abuse that, in the opinion of the Investigator, are likely to affect the subject's response to treatment or the ability to complete the study.
- •The subject has a history of any kind of malignant tumor (not including basal cell skin cancer).
- •The subject has clinical evidence of any diabetes-related complication that in the opinion of the Investigator would interfere with the subject's participation in and/or completion of the study.
- •Subject has history of endogenous allergic reactivity:
- •Severe allergic reaction or severe exacerbation of allergic asthma within 12 months prior to the Screening-Ext Visit.
- •Ongoing systemic asthma treatment.
- •Subjects with history of life threatening or severe allergy, re-occurrence of which cannot be ruled out based on the Investigator's judgment.
- •The subject has known allergy to lipid emulsions.
- •The subject has a known immune deficiency from any disease, or a condition associated with an immune deficiency.
- •The subject is receiving immunosuppressive or immunomodulating agents or cytotoxic therapy or any medication that in the opinion of the Investigator might interfere with the study.
- •The subject has any of the following clinically significant laboratory abnormalities:
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than three times the upper limit of the normal (ULN) at the Screening-Ext Visit.
- •Total bilirubin greater than 1.3 times the ULN at the Screening-Ext Visit.
- •Subjects with severe renal failure at the Screening-Ext visit (as defined by glomerular filtration rate < 30 mL/min/1.73 m2 by Cockroft und Gault calculation • Clinically significant laboratory abnormalities, confirmed by repeat measurement, which may interfere with the assessment of safety and / or efficacy of the study drug, other than hyperglycemia and glycosuria at the Screening-Ext Visit.
- •Fasting triglycerides <1000 mg/dL (11.3 mmol/L) at the Screening-Ext Visit. Suitable medical therapy for treatment of hyperlipidemia is allowed.
- •The subject is a known or suspected drug abuser.
- •The subject is known to test positive for HIV antibodies.
- •The subject has chronic hematologic disease.
- •The subject has liver disease such as cirrhosis or chronic active hepatitis.
研究组 & 干预措施
DiaPep277®
Experimental
干预措施: DiaPep277® (Drug)
结局指标
主要结局
efficacy will be measured by comparing Hemoglobin A1c
时间窗: two years
次要结局
- Safety will be evaluated calculating number of Adverse Events.(two years)
研究者
相似试验
已完成
2 期
Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 DiabetesType 1 DiabetesNCT02411253Assistance Publique - Hôpitaux de Paris141
招募中
1 期
Immunotherapy with Autologous Tregs in T1DMType 1 Diabetes MellitusNCT06708780The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School20
招募中
不适用
Characterization of Autoreactive Regulatory and Conventional CD4 T Cells in Recent Onset Type 1 Diabetes and Control IndividualsType 1 DiabetesNCT06427421Assistance Publique - Hôpitaux de Paris80
已完成
1 期
Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 DiabetesHealthyType 1 DiabetesNCT00896077DiaKine Therapeutics, Inc.8
已完成
1 期
Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De)Type 1 DiabetesNCT02620332King's College London27